Related references
Note: Only part of the references are listed.A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2010)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data
Viera Lukacova et al.
AAPS JOURNAL (2009)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei et al.
AAPS JOURNAL (2009)
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite
Xin Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
Masoud Jamei et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Human clearance prediction: shifting the paradigm
Thierry Lave et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
The Simcyp® Population-based ADME Simulator
Masoud Jamei et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power
Trevor N. Johnson et al.
PHARMACEUTICAL STATISTICS (2009)
Physiology-Based Simulations of a Pathological Condition Prediction of Pharmacokinetics in Patients with Liver Cirrhosis
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2008)
Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling
F. Bouzom et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2008)
Characterizing uncertainty and variability in physiologically based pharmacokinetic models: State of the science and needs for research and implementation
Hugh A. Barton et al.
TOXICOLOGICAL SCIENCES (2007)
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -: CYP2C9 and warfarin as an example
Gemma L. Dickinson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application
Gemma L. Dickinson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
Stefan Willmann et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole
Jenny Y. Chien et al.
DRUG METABOLISM AND DISPOSITION (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2006)
Development and evaluation of a generic physiologically based pharmacokinetic model for children
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2006)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Tissue distribution of basic drugs:: Accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
T Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics
LM Berezhkovskiy
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
The effects of dose staggering on metabolic drug-drug interactions
JS Yang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution
P Poulin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate
GJ Muirhead et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers
GJ Muirhead et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir
GJ Muirhead et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
S Kanamitsu et al.
PHARMACEUTICAL RESEARCH (2000)
Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
S Kanamitsu et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
